Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00259987
Status:
COMPLETED
Last Update Posted:
2009-05-18
First Post:
2005-11-30
Brief Title:
Effects Of Lapatinib GW572016 In Patients With Relapsed Adenocarcinoma Of The Esophagus
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Phase II Open-Label Study Evaluating Clinical Efficacy Safety Pharmacokinetic and Pharmacodynamic Effects of Lapatinib GW572016 in Patients With Relapsed Adenocarcinoma of the Esophagus Including Tumors of the Gastroesophageal Junction and Gastric Cardia
Status:
COMPLETED
Status Verified Date:
2009-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Phase II study will assess the efficacy safety and pharmacodynamics and pharmacokinetics of 1000 mg and 1500 mg lapatinib administered once daily in patients with relapsed adenocarcinoma of the esophagus including tumors of the GE junction and gastric cardia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None